英文字典中文字典


英文字典中文字典51ZiDian.com



中文字典辞典   英文字典 a   b   c   d   e   f   g   h   i   j   k   l   m   n   o   p   q   r   s   t   u   v   w   x   y   z       







请输入英文单字，中文词皆可：


请选择你想看的字典辞典：
单词字典翻译
291144查看　291144　在百度字典中的解释百度英翻中〔查看〕
291144查看　291144　在Google字典中的解释Google英翻中〔查看〕
291144查看　291144　在Yahoo字典中的解释Yahoo英翻中〔查看〕

安装中文字典英文字典查询工具!


中文字典英文字典工具:
选择颜色:
输入中英文单字

































































英文字典中文字典相关资料:


  • LIBTAYO® (cemiplimab-rwlc) in Advanced NSCLC, BCC, CSCC . . .
    Learn about LIBTAYO® (cemiplimab-rwlc) in the treatment of advanced NSCLC, BCC, CSCC, as an adjuvant treatment for high-risk CSCC Review Important Safety Info Full Prescribing Information including Med Guide
  • LIBTAYO® (cemiplimab-rwlc) | Official HCP Website
    LIBTAYO® (cemiplimab-rwlc) is a prescription medicine indicated for the treatment of adult patients with advanced NSCLC, CSCC, BCC, and as an adjuvant treatment for high-risk CSCC See Important Safety full Prescribing Information
  • Libtayo: Uses, Side Effects, Warnings - Drugs. com
    Libtayo (cemiplimab-rwlc) is used to treat metastatic cutaneous squamous cell carcinoma, basal cell carcinoma, and non-small cell lung cancer Includes Libtayo side effects, interactions and indications
  • Cemiplimab (Libtayo®) - ChemoExperts
    Treatment Name: Cemiplimab (Libtayo®) Cemiplimab (Libtayo®) is an Immunotherapy Regimen for Lung Cancer, Non-Small Cell Lung Cancer (NSCLC) How does cemiplimab work? Cemiplimab is designed to block the signals that tumor cells use to suppress the immune system allowing the immune system to attack the lung cancer cells Goals of therapy:
  • Cemiplimab - Wikipedia
    Cemiplimab, sold under the brand name Libtayo, is a monoclonal antibody medication used for the treatment of squamous cell skin cancer [7][8] Cemiplimab belongs to a class of drugs that binds to the programmed death receptor-1 (PD-1), blocking the PD-1 PD-L1 pathway [6][9]
  • Libtayo® (cemiplimab-rwlc) Approved in the U. S. as First and . . .
    The FDA evaluated Libtayo under Priority Review, which is reserved for medicines that represent potentially significant improvements in efficacy or safety in the treatment of serious conditions An additional regulatory application is also under review in the European Union, with a decision expected by the first half of 2026
  • FDA approves cemiplimab-rwlc for adjuvant treatment of . . .
    On October 8, 2025, the Food and Drug Administration approved cemiplimab-rwlc (Libtayo, Regeneron Pharmaceuticals Inc ) for the adjuvant treatment of adults with cutaneous squamous cell carcinoma
  • Cemiplimab-rwlc (Libtayo®) - OncoLink
    Cemiplimab-rwlc is a type of monoclonal antibody therapy used in the treatment of some cases of cutaneous squamous cell carcinoma
  • Cemiplimab-rwlc (Libtayo) Updates 2025: Uses in cancer, Side . . .
    This article is about Cemiplimab-rwlc (Libtayo), its uses, side effects, dosage, and what to expect during treatment
  • Cemiplimab-rwlc (intravenous route) - Side effects uses
    Description Cemiplimab-rwlc injection is used to treat a type of skin cancer called cutaneous squamous cell carcinoma (CSCC) that has spread (metastatic) or cannot be cured by surgery or radiation (locally advanced)





中文字典-英文字典  2005-2009